Cibus, a leader in precision gene editing in agriculture, and GDM, a leading global soybean research company, today announced a strategic collaboration focused on developing and delivering new solutions for challenges faced by soybean farmers.
FibroGen, Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion relating to the use of roxadustat for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).
LiquiGlide, the inventors of a breakthrough technology that's revolutionizing products, packaging, processes, and patient experiences by eliminating the friction between solids and liquids, has announced that the U.S. Food and Drug Administration (FDA) has accepted a Device Master File (MAF) from LiquiGlide's biomedical division for its novel, patented coating platform.
Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This partnership is expected to fuel the expansion of the combined company’s capabilities to help enable the development and potential approvals of important cancer treatments.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA™ (loncastuximab tesirine-lpyl) has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines) in oncology for B-cell Lymphomas.
SAN DIEGO – May 4, 2021 – Cibus, a leader in precision gene editing and trait development in agriculture, welcomes the published findings of the European Commission’s New Genomics Techniques (NGTs) study.
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Applications (sNDAs) for lumateperone, an investigational agent for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate.
The company's $13.5M round and additional partnerships with Colgate, the Mibelle Group and Yves Béhar prove technology's ability to create market-viable solutions for no-waste products, packaging, and manufacturing processes.
Today LiquiGlide, the company spun out of MIT’s Varanasi Research Group to develop ways to manufacture and commercialize the technology, announced a new $13.5 million round of funding. But more importantly for consumers, the company also revealed a new partnership with Colgate.
ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA™ (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma.
FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD).
FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD).
The goal of the 2021 Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation is to source innovative solutions to improve outcomes and experiences for all those affected by transplantation.
Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments.
Backed by M12 - Microsoft's Venture Fund and Playground Global, 1910 Genetics will scale its AI and biological automation platforms, build its world-class team, expand partnerships with biopharma companies and advance its pipeline of therapeutic programs
ITCI submits Supplemental New Drug Applications (sNDAs) for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults.
Cibus, a leader in precision gene editing in agriculture, today announced that its first field trials have confirmed greenhouse results of a non-GMO trait that provides tolerance to white mold (Sclerotinia). This milestone represents a major step in Cibus’ mission to breed a durable resistant plant with its Rapid Trait Development System (RTDSTM), as well as a breakthrough for a complex challenge that GMO and traditional technologies have been unable to fully address. This trait is among Cibus’ 14 trait products that the US Department of Agriculture, under its “Am I Regulated” process, has recently ruled were not subject to regulation under 7 CFR Part 340 and instead are regulated in the same manner as traits developed using conventional breeding practices.
Genome editing techniques that modify the DNA of plants do not pose more hazards than conventional breeding or techniques that introduce new DNA into a plant, an EFSA assessment concludes.
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and granted priority review status. The FDA has set a Prescription Drug User Fee Act (“PDUFA”) target date of May 21, 2021.
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2020 and updated full-year 2020 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).